These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17327829)

  • 1. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
    Nasu Y; Saika T; Ebara S; Kusaka N; Kaku H; Abarzua F; Manabe D; Thompson TC; Kumon H
    Mol Ther; 2007 Apr; 15(4):834-40. PubMed ID: 17327829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
    Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
    Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
    Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
    Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
    van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
    Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
    Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
    Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
    Tang Q; Zhang D; Wan M; Jin L
    Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
    Eastham JA; Chen SH; Sehgal I; Yang G; Timme TL; Hall SJ; Woo SL; Thompson TC
    Hum Gene Ther; 1996 Mar; 7(4):515-23. PubMed ID: 8800746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
    Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
    Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer.
    Atkinson G; Hall SJ
    Urology; 1999 Dec; 54(6):1098-104. PubMed ID: 10604717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer.
    Hsiao WC; Sung SY; Chung LWK; Hsieh CL
    Methods Mol Biol; 2019; 1895():27-42. PubMed ID: 30539527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
    Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity.
    Cheon J; Kim HK; Moon DG; Yoon DK; Cho JH; Koh SK
    BJU Int; 2000 Apr; 85(6):759-66. PubMed ID: 10759680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
    Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
    Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
    Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
    J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
    Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
    Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
    Freytag SO; Stricker H; Pegg J; Paielli D; Pradhan DG; Peabody J; DePeralta-Venturina M; Xia X; Brown S; Lu M; Kim JH
    Cancer Res; 2003 Nov; 63(21):7497-506. PubMed ID: 14612551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of adenovirus-mediated HSV-tk/GCV system on lens epithelium].
    Wang B; Weng J
    Zhonghua Yan Ke Za Zhi; 2002 Oct; 38(10):618-22. PubMed ID: 12487913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer.
    Hall SJ; Mutchnik SE; Chen SH; Woo SL; Thompson TC
    Int J Cancer; 1997 Jan; 70(2):183-7. PubMed ID: 9009158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.